Andrew X. Zhu
Oncologist who led REACH-2, the first positive biomarker-selected trial in liver cancer, which established ramucirumab for patients with a high alpha-fetoprotein level.
Overview
Andrew Zhu led the liver cancer programme at Massachusetts General Hospital for many years. He was first author of the 2019 Lancet Oncology report of REACH-2, which showed that ramucirumab lengthened survival compared with placebo in previously treated hepatocellular carcinoma with alpha-fetoprotein of 400 ng/mL or more, the first positive phase 3 trial in liver cancer to select patients by a biomarker. He has also led trials of ivosidenib in IDH1-mutant cholangiocarcinoma.
Similar pages
not linked directly; found by shared links- PersonRobin Kate Kelley
Shares Intrahepatic cholangiocarcinoma, Hepatocellular carcinoma and the tags hcc, biliary, trialist.
- PersonGhassan K. Abou-Alfa
Shares Hepatocellular carcinoma and the tags hcc, biliary, trialist.
- PersonJordi Bruix
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tags hcc, trialist.
- PersonJohn N. Primrose
Shares Intrahepatic cholangiocarcinoma and the tags biliary, trialist.
- TrialOri-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.
- TrialA Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.
- PersonAngela Lamarca
Shares the tags biliary, trialist.
- PersonMasatoshi Kudo
Shares Hepatocellular carcinoma and the tags hcc, trialist.